Short answer: No combination studies; both have documented effects on heart rate or blood pressure.
- FlagCaution
- EvidenceMechanism only
- Sources3
- Last reviewedOctober 22, 2026
What is known
No human studies of these two together were found. The Vyleesi (PT-141) label says each dose briefly raises blood pressure and lowers heart rate. The FDA says it has identified serious adverse events with CJC-1295, including increased heart rate and a widespread blood-vessel-widening reaction. Whether these effects add up or offset each other has not been studied; people with heart disease or high blood pressure should be cautious.
CJC-1295 raised growth hormone 2- to 10-fold for 6 days or more after one injection in healthy adults. The bremelanotide development program advised caution in people at risk of cardiovascular disease and well-controlled blood pressure during treatment. PT-141 is approved only for premenopausal women with low sexual desire; CJC-1295 is not approved.
How strong the evidence is
Mechanism only. Theoretical. No study tested the pair; the concern comes from documented effects of each compound on its own. Caution: There is a documented or likely risk to watch for, such as low blood sugar or added side effects. Talk to your prescriber before combining.
Guides: PT-141, CJC-1295. To check this pair alongside others, open it in the peptide interaction checker.
Education only, not medical advice. "No known interaction" means we found nothing reported, not that a combination is safe. Most of the peptides here are not FDA approved, and most pairs have never been studied together in people. Talk to your clinician or pharmacist before you start, stop or combine anything.
Sources
- Cosette Pharmaceuticals, Inc. VYLEESI (bremelanotide) injection - prescribing information. FDA label (DailyMed), 2025
Label: transient increases up to 6 mmHg systolic and 3 mmHg diastolic blood pressure and heart rate reduction up to 5 bpm after each dose.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA web page (content current as of 04/22/2026), 2026
Says FDA has identified serious adverse events with CJC-1295, including increased heart rate and systemic vasodilatory reaction; clinical data are limited.
- Clayton AH, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt), 2022. PMID 35147466
Across 3500 subjects, bremelanotide caused small transient blood pressure increases; authors advise caution in patients at cardiovascular risk.
Other reviewed pairs with PT-141
Other reviewed pairs with CJC-1295